Analysts Set Expectations for PMN Q2 Earnings

Promis Neurosciences (NASDAQ:PMN) – Research analysts at Brookline Capital Markets issued their Q2 2026 earnings per share (EPS) estimates for shares of Promis Neurosciences in a note issued to investors on Wednesday, May 20th. Brookline Capital Markets analyst F. Ahmed anticipates that the company will earn ($2.09) per share for the quarter. Brookline Capital Markets has a “Strong-Buy” rating on the stock. Brookline Capital Markets also issued estimates for Promis Neurosciences’ Q3 2026 earnings at ($2.41) EPS, Q4 2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($2.32) EPS, Q2 2027 earnings at ($1.02) EPS, Q3 2027 earnings at ($1.15) EPS and Q4 2027 earnings at ($0.98) EPS.

Promis Neurosciences (NASDAQ:PMN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.20).

Several other equities analysts have also weighed in on PMN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Promis Neurosciences in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Promis Neurosciences to a “strong sell” rating in a research report on Saturday, February 14th. Finally, Guggenheim decreased their price objective on Promis Neurosciences from $125.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Promis Neurosciences presently has an average rating of “Moderate Buy” and an average price target of $26.50.

Promis Neurosciences Trading Up 2.4%

Promis Neurosciences stock opened at $10.85 on Friday. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $39.75. The stock has a market cap of $97.32 million, a P/E ratio of -0.75 and a beta of -0.20. The company has a 50-day moving average price of $13.00 and a 200 day moving average price of $12.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PMN. Ally Bridge Group NY LLC lifted its holdings in Promis Neurosciences by 367.1% during the 3rd quarter. Ally Bridge Group NY LLC now owns 6,233,497 shares of the company’s stock worth $2,649,000 after buying an additional 4,899,069 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Promis Neurosciences by 39.1% in the third quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock worth $1,264,000 after acquiring an additional 836,622 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Promis Neurosciences during the first quarter worth $16,418,000. Yu Fan purchased a new stake in shares of Promis Neurosciences during the first quarter worth $4,188,000. Finally, Citadel Advisors LLC raised its stake in shares of Promis Neurosciences by 168.1% in the third quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock valued at $72,000 after acquiring an additional 106,650 shares in the last quarter. Institutional investors and hedge funds own 50.13% of the company’s stock.

Insider Buying and Selling at Promis Neurosciences

In other news, Director Patrick D. Kirwin bought 4,000 shares of the company’s stock in a transaction on Wednesday, April 22nd. The stock was bought at an average cost of $11.33 per share, with a total value of $45,320.00. Following the transaction, the director directly owned 4,653 shares in the company, valued at $52,718.49. The trade was a 612.56% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Eugene Williams purchased 2,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were acquired at an average price of $24.00 per share, for a total transaction of $48,000.00. Following the completion of the purchase, the director directly owned 12,397 shares of the company’s stock, valued at approximately $297,528. This trade represents a 19.24% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 7,000 shares of company stock worth $115,850 in the last quarter. Company insiders own 1.50% of the company’s stock.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.